Alkaline Citrate Treatment to Lower the Risk of Nephrocalcinosis in Preterm Infants
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Preterm infants are at risk to develop nephrocalcinosis. Incidence numbers vary according to birth weight and gestation age. Very low birth weight infants have the highest risk index, with ~ 7-10 % of preterm infants developing nephrocalcinosis in the patient population. We, the researchers at the University of Cologne, and others found significantly decreased urinary citrate excretion (hypocitraturia) to be one of the main risk factors. Hence, we hypothesized, that prophylactic treatment with oral alkaline citrate solution (Shol's solution) would help to 1) increase urinary citrate excretion and 2) help to decrease the incidence of nephrocalcinosis.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
up to 8 Weeks (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Preterm infants < 32 weeks gestation age and < 1500 g birth weight
Cardial, renal or gastrointestinal malformations
Chronic renal failure
Therapy with vitamin B6
High dose treatment with furosemide or dexamethasone
Severe metabolic alkalosis
Worse clinical condition of preterm infant, which makes oral feeding impossible